

## Belimumab (Benlysta®)

Along with this order form, please include the following: Demographics, Insurance Information, Lab Results, Current Medications, and Recent Visit Notes. ArrIVE Infusion will obtain any necessary medication authorizations for patients receiving infusion therapies.

Order Date: \_\_\_\_/\_\_\_\_/\_\_\_\_

Referral Status: ☐ New Referral ☐ Dose or Frequency Change ☐ Renewal

| <b>Patient Name:</b> _____<br><b>Patient Address:</b> _____<br><b>Patient Phone Number:</b> _____<br><b>Date of Birth:</b> ____/____/____<br><b>Weight:</b> ____ kg <b>Height:</b> ____ cm<br><b>Allergies:</b> _____   | <b>Primary Insurance:</b> _____<br><b>Member ID:</b> _____<br><b>Secondary Insurance:</b> _____<br><b>Member ID:</b> _____   |           |           |   |   |                                     |  |                                       |   |
|---|--|-----------|-----------|---|---|-------------------------------------|--|---------------------------------------|---|
| <p style="text-align: center;"><b>Diagnosis</b></p> <input type="checkbox"/> Drug-induced systemic lupus erythematosus (M32.0)<br><input type="checkbox"/> Systemic lupus erythematosus organ or system involvement unspecified (M32.10)<br><input type="checkbox"/> Endocarditis in systemic lupus erythematosus (M32.11)<br><input type="checkbox"/> Pericarditis in systemic lupus erythematosus (M32.12)<br><input type="checkbox"/> Lung involvement in systemic lupus erythematosus (M32.13)<br><input type="checkbox"/> Glomerular disease in systemic lupus erythematosus (M32.14)<br><input type="checkbox"/> Tubulo-interstitial nephropathy in systemic lupus erythematosus (M32.15)<br><input type="checkbox"/> Other organ or system involvement in systemic lupus erythematosus (M32.19)<br><input type="checkbox"/> Other forms of systemic lupus erythematosus (M32.8)<br><input type="checkbox"/> Systemic lupus erythematosus, unspecified (M32.9)<br><input type="checkbox"/> Other Diagnosis Code (ICD-10): _____<br><input type="checkbox"/> Other Indication: _____<br>Target start date: _____ | <table style="width: 100%;"> <tr> <th style="text-align: left;">Labs</th> <th style="text-align: left;">Frequency</th> </tr> <tr> <td><input type="checkbox"/> CMP</td> <td><input type="checkbox"/> Every infusion</td> </tr> <tr> <td><input type="checkbox"/> CBC w/diff</td> <td><input type="checkbox"/> Other: _____</td> </tr> <tr> <td><input type="checkbox"/> CBC w/o diff</td> <td></td> </tr> </table>             | Labs      | Frequency | <input type="checkbox"/> CMP              | <input type="checkbox"/> Every infusion | <input type="checkbox"/> CBC w/diff | <input type="checkbox"/> Other: _____  | <input type="checkbox"/> CBC w/o diff |   |
| Labs  | Frequency  |           |           |   |   |                                     |  |                                       |   |
| <input type="checkbox"/> CMP  | <input type="checkbox"/> Every infusion  |           |           |   |   |                                     |  |                                       |   |
| <input type="checkbox"/> CBC w/diff   | <input type="checkbox"/> Other: _____  |           |           |   |   |                                     |  |                                       |   |
| <input type="checkbox"/> CBC w/o diff   |  |           |           |   |   |                                     |  |                                       |   |
| Previously tried and failed therapies (include dates): _____  |  |           |           |   |   |                                     |  |                                       |   |
| <p><b>Belimumab (Benlysta)</b></p> <p><b>Dose</b></p> <input type="checkbox"/> 10 mg/kg<br><input type="checkbox"/> ____ mg/kg<br><input type="checkbox"/> ____ mg  | <table style="width: 100%;"> <tr> <th style="text-align: left;">Induction</th> <th style="text-align: left;">Frequency</th> </tr> <tr> <td><input type="checkbox"/> On weeks 0, 2, 4</td> <td><b>Maintenance</b></td> </tr> <tr> <td></td> <td><input type="checkbox"/> Every 4 weeks</td> </tr> <tr> <td></td> <td><input type="checkbox"/> Every ____ weeks</td> </tr> </table> <p>Date of last infusion: ____/____/____</p> | Induction | Frequency | <input type="checkbox"/> On weeks 0, 2, 4 | <b>Maintenance</b>                      |                                     | <input type="checkbox"/> Every 4 weeks |                                       | <input type="checkbox"/> Every ____ weeks |
| Induction   | Frequency  |           |           |   |   |                                     |  |                                       |   |
| <input type="checkbox"/> On weeks 0, 2, 4   | <b>Maintenance</b>   |           |           |   |   |                                     |  |                                       |   |
|   | <input type="checkbox"/> Every 4 weeks   |           |           |   |   |                                     |  |                                       |   |
|   | <input type="checkbox"/> Every ____ weeks  |           |           |   |   |                                     |  |                                       |   |

|   |   |   |
|---|---|---|
| <b>Pre-Medications and Pre-Protocol</b><br>(ordered at physician discretion)  | <input type="checkbox"/> Acetaminophen 650 mg PO once<br><input type="checkbox"/> Loratadine 10 mg PO once<br><input type="checkbox"/> Diphenhydramine once<br><input type="checkbox"/> 25 mg <input type="checkbox"/> 50 mg<br><input type="checkbox"/> PO <input type="checkbox"/> IV<br><input type="checkbox"/> Famotidine 20 mg IV once<br><input type="checkbox"/> Hydrocortisone 100 mg IV once<br><input type="checkbox"/> Methylprednisolone 125 mg IVP once<br><input type="checkbox"/> Other: _____  | <b>Hydration</b><br><input type="checkbox"/> LR<br><input type="checkbox"/> Sodium Chloride 0.9%<br><input type="checkbox"/> Other _____<br><br>_____ mL at _____ mL/hr<br><input type="checkbox"/> Before <input type="checkbox"/> During <input type="checkbox"/> Following |
| <b>Flushing Protocol</b><br>(pre and post medication)   | <input type="checkbox"/> Sodium Chloride 0.9% <input type="checkbox"/> 5 mL <input type="checkbox"/> 10 mL<br>as needed for line care   | <input type="checkbox"/> Heparin _____ Units/mL   _____ mL<br>as needed for line care   |
| <b>Hypersensitivity Panel</b><br>Together Care Hypersensitivity Panel will be ordered to provide emergency supportive care medication therapy as necessary.   | <ul style="list-style-type: none"> <li>• <b>Sodium chloride</b> 0.9% bolus 500 mL once as needed for hypotensive management (SBP &lt;90mmHg)</li> <li>• <b>Acetaminophen</b> 650 mg once as needed for temperature GREATER than 38 C (100.4 F), headaches, generalized pain, back pain, abdominal cramping</li> <li>• <b>Albuterol</b> 2.5 mg /3 mL (0.083%) nebulizer solution 2.5 mg, nebulize every 10 min PRN, hypoxemia, bronchospasm, wheezing, dyspnea, for 2 doses</li> <li>• <b>Albuterol HFA</b> inhaler 2 puffs q4hs as needed for hypoxemia, bronchospasm, wheezing, dyspnea</li> <li>• <b>Epinephrine</b> injection 0.3 mg IM every 15 minutes as needed for SBP less than 90mmHg, mild to moderate anaphylaxis for 3 doses</li> <li>• <b>Famotidine</b> injection 20 mg IV over 2 minutes once as needed for severe hypersensitivity/infusion reaction including systolic BP 80-90 mmHg, bradycardia or tachycardia, hypoxemia, dyspnea, cognitive changes, generalized rash, chest pain/pressure</li> <li>• <b>Diphenhydramine</b> injection 25 mg IV over 1 minute once as needed, moderate hypersensitivity/infusion reaction (grade 2) including temperature greater than 100.5, rigors, localized rash/hives, vomiting, nausea, pruritis, flushing, dizziness, back pain, abdominal cramping, uneasiness, agitation, feeling of impending doom</li> <li>• <b>Diphenhydramine</b> injection 50 mg IV over 1 minute once as needed for severe hypersensitivity/infusion reaction (grade 3), including systolic BP 80-90 mmHg, bradycardia or tachycardia, hypoxemia, dyspnea, cognitive changes, generalized rash, chest pain/pressure</li> <li>• <b>Hydrocortisone</b> sodium succinate injection 100 mg IV once as needed for severe hypersensitivity/infusion reaction (grade 3), including systolic BP 80-90 mmHg, bradycardia or tachycardia, hypoxemia, dyspnea, cognitive changes, generalized rash, chest pain/pressure</li> </ul> |   |
| <div> <div> Provider Name: _____ </div> <div> Provider Signature: _____ </div> </div> <div> <div> Attending Physician Name: _____ </div> <div> Provider NPI: _____ </div> </div> <div> <div> Office Phone Number: _____ </div> <div> Office Fax Number: _____ </div> </div> <p><i>(If ordering provider is an advanced practice practitioner)</i><br/> <i>Note: This order is valid for 12 months from date of physician signature.</i></p> |   |   |